
Thank you, Dr. Cyrielle Caussy, for joining us from Lyon, France, to discuss the role of resmetirom in the endocrinology clinic! @DrLoomba #MASHDAY2026 #MASH #MASLD #MASHEDUCATIONDAY

MASLD Research Center @ UCSD

Thank you, Dr. Cyrielle Caussy, for joining us from Lyon, France, to discuss the role of resmetirom in the endocrinology clinic! @DrLoomba #MASHDAY2026 #MASH #MASLD #MASHEDUCATIONDAY

Dr. Eduardo Grunvald’s talk on the role of GLP-1 receptor agonists in obesity and type 2 diabetes, highlighting their impact on metabolic health. @DrLoomba #MASHDAY2026 #MASH #MASLD #MASHEDUCATIONDAY

Dr. Irvine Vodkin’s talk on MASH, Cirrhosis, and Liver Transplantation. A very thorough discussion with valuable clinical perspectives. @DrLoomba #MASHDAY2026 #MASH #MASLD #MASHEDUCATIONDAY

Dr. Harpreet Bhatia’s talk on cardiovascular disease and lipid management in patients with MASLD and significant fibrosis. A valuable discussion on an important aspect of MASLD care. @DrLoomba #MASHDAY2026 #MASH #MASLD #MASHEDUCATIONDAY

Great talk by @MonicaTincopa on MASH, Disparities, and Liver Cancer. A fascinating discussion! @DrLoomba #MASHDAY2026 #MASH #MASLD #MASHEDUCATIONDAY

Dr. Cynthia Behling's talk on Patient Liver Biospy. An excellent look at the role of liver biopsy in patient care! @DrLoomba #MASHDAY2026 #MASH #MASLD #MASHEDUCATIONDAY

Great presentation by @AjmeraVeeral on Patient Presentation to Clinic: Application of Care Pathways. Really enjoyed learning about the application of care pathways in clinical practice! @DrLoomba #MASHDAY2026 #MASHEDUCATIONDAY #MASH #MASLD

Thank you, @DrHuangDQ, for recording your talk on the Natural History of MASLD and Disease Progression! Such an informative and insightful presentation. @DrLoomba #MASH #MASHDAY2026 #MASHEDUCATIONDAY #MASLD

Kicking off #MASHDAY2026 with Dr. Ajmera's talk on MASLD Pre-Test, Nomenclature and an Introduction to the MASLD Patient Journey. @DrLoomba @AjmeraVeeral #MASH #MASHEDUCATIONDAY

Strong work Maria Mironova @UCSD_GI fellow PREVALENCE AND RISK FACTORS ASSOCIATED WITH MASLD AND ADVANCED FIBROSIS AMONG OVERWEIGHT INDIVIDUALS: IMPLICATIONS FOR SCREENING GUIDELINES. ovid.com/10.14309/ajg.000000… @AASLDtweets @UCSDHealth @AmCollegeGastro @AmerGastroAssn @INASL_Liver

Please to share our article co-authored by @DrLoomba, ALG-055009 shows promise in reducing liver fat and improving lipid profiles in non-cirrhotic MASH patients with a favorable safety profile! thelancet.com/journals/langa… @UCSD_GI @LancetGastroHep

New research - ALG-055009 in non-cirrhotic adults with metabolic dysfunction-associated steatohepatitis (HERALD): a randomised, double-blind, placebo-controlled, phase 2a trial thelancet.com/journals/langa… @DrLoomba #MASH #MASLD #LiverTwitter #MedTwitter

Pleased to share our review on MetALD co-authored with @LuisAntonioDiaz @IsraelsenMads @PoseElisa - such a great pleasure working with them on this piece. @rabataller @QAnstee @AASLDtweets @BavenoCoop @EASLnews @UCSD_GI @Dr_Vijay_Shah @AmerGastroAssn nature.com/articles/s41575-0…

Efficacy and safety of zalfermin co-administered with semaglutide in stage 2-4 fibrosis in MASH sciencedirect.com/science/ar… @AASLDtweets @EASLnews @wonglaihung @DrHuangDQ @Rob__Brierley @MASLDResearch @mashtagconf @precisionliver


Excited to share the publication of our latest work in @LancetGastroHep evaluating zalfermin and semaglutide in patients with metabolic dysfunction-associated steatohepatitis (MASH) and advanced fibrosis. 🎉@DrLoomba and the entire study team!